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End-stage renal disease patients (ESRD) suffer from procoagulant abnormalities that lead to excessive 
cardiovascular events, as well as from platelet dysfunction manifesting as an increased risk of bleeding. The 
exact pathogenesis of complex hemostatic disorders in ESRD patients is not completely understood. The 
aim of our study was to investigate the possible different effects of hemodialysis (HD) and peritoneal dial-
ysis (PD) on platelet function in patients with ESRD by using the platelet function analyzer (PFA-100) which 
in vitro simulates the process of aggregation and platelet activation. Tests were performed with collagen/
epinephrine (COL/EPI) and collagen/adenosine-5-diphosphate (COL/ADP) cartridges. The study included 
44 patients with ESRD undergoing regular HD (n=32) or PD (n=12). Although there were no significant dif-
ferences in COL/EPI and COL/ADP tests, it is indicative that more than 50% of HD patients had COL/EPI 
test values above the upper limit. These findings correlated with a higher chance for bleeding in HD group. 
Additionally, patients in HD group were significantly older and had significantly lower platelet count compared 
to PD patients. 
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INTRODuCTION
Hemostatic disorders are common complications in pa-
tients with end-stage renal disease (ESRD), mainly in 
the form of bleeding diathesis, but also as an increased 
risk of thrombotic events. In terms of abnormalities of 
primary hemostasis, platelet dysfunction and impaired 
interaction between platelets and vessel wall are consid-
ered as the main factors responsible for bleeding tenden-
cies(1-3). Anemia and accumulation of medication due to 
poor clearance are also important factors in impaired 
hemostasis in ESRD patients(1). On the other hand, the 
high mortality rate in ESRD patients is mainly due to the 
increased incidence of thrombotic and cardiovascular 
complications despite decreased platelet function(3). He-
mostatic abnormalities in ESRD, to some extent, may be 
affected by the choice of renal replacement therapy(4,5). 
Patients on hemodialysis (HD) have an increased risk 
of thrombotic events, primarily due to the release of 
thromboxane A2 and ADP into the circulation and also 
platelet degranulation. Some activation of platelets oc-
curs due to the exposure of blood to the roller pump seg-
ment(2,3,5). On the other hand, the hemodialysis process 
itself may contribute to hemorrhagic tendencies1, while 
uremic toxins present in circulating blood can be partial-
ly responsible for platelet dysfunction which can lead to 
bleeding diathesis. Patients on peritoneal dialysis (PD) 
showed evidence of a higher degree of hypercoagulation 
than HD patients(2,3). The exact pathogenesis of complex 
hemostatic disorders in patients with ESRD is not com-
pletely understood. 
The aim of our study was to investigate the possible dif-
ferent effects of HD and PD on platelet function in pa-
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tients with ESRD by using the platelet function analyzer 
(PFA-100) which in vitro simulates the process of aggre-
gation and platelet activation.
PATIENTS AND METHODS
The study included patients with ESRD on two different 
types of renal replacement therapy (HD and continuous 
ambulatory peritoneal dialysis, CAPD), treated at the 
Department of Nephrology, Hypertension, Dialysis and 
Transplantation, Zagreb university Hospital Center, dur-
ing a 3-month period. On regular patient visit, together 
with blood sampling for standard laboratory parameters, 
an additional 2 mL of blood was obtained from all pa-
tients that met the inclusion criteria, after providing their 
informed consent. Ethical approval was obtained from 
the Ethics Board of the Zagreb university Hospital Cent-
er. Platelet function testing was performed on a platelet 
function analyzer (PFA-100) which in vitro simulates 
the process of aggregation and platelet activation. The 
tests were performed with collagen/epinephrine (COL/
EPI) and collagen/adenosine-5-diphosphate (COL/ADP) 
cartridges. Results are reported as the closure times in 
seconds for COL/EPI (increased by aspirin and nonster-
oidal anti-inflammatory drugs, NSAID) and COL/ADP 
cartridges (variably affected by ADP receptor disorders 
and clopidogrel). The ranges considered normal were 85-
165 s for the COL/EPI closure time and 71-118 s for the 
COL/ADP. Data for analysis were taken from medical 
records. 
PATIENTS
The study was performed on 44 ESRD patients under-
going regular HD or PD. The group of patients on HD 
included 32 patients (19 male and 13 female, median age 
62), while the PD group included 12 patients (5 male and 
7 female, median age 51). The cause of ESRD was hyper-
tension in 12, diabetic nephropathy in seven, glomeru-
lonephritis and pyelonephritis in nine, hemolytic uremic 
syndrome/thrombotic thrombocytopenic purpura (HuS/
TTP) in two and congenital diseases in seven patients, 
whereas in seven patients the cause of renal failure was 
unknown. The patients included in the study received 
all their regular medications except for drugs that affect 
platelet function (aspirin, anticoagulants, nonsteroidal 
anti-rheumatic drugs). Statins were used by two (6.3%) 
patients in HD group and 9 (75%) patients in PD group. 
In HD group, 24 (75%) patients received erythropoietin 
therapy, while in CAPD group only two (16.7%) patients 
received erythropoietin therapy. All but two patients 
in HD group were administered low-molecular-weight 
heparin (LMWH, nadroparin or enoxaparin). Patients in 
PD group did not receive LMWH. All patients in both 
groups signed their informed consent. 
IN VITRO CLOSuRE TIME TEST 
The Platelet Function Analyzer (PFA-100, Siemens 
Healthcare Diagnostics) is a tool that can detect abnor-
malities of primary hemostasis in small blood samples. 
It measures the time required for the platelet plug from 
citrated blood aspirated under control flow conditions 
through a 150-micrometer aperture to occlude the aper-
ture (closure time). The system monitors platelet inter-
action on collagen-ADP (COL-ADP) or collagen-epine-
phrine (COL-EPI) coated membranes(3,4). In vitro closure 
time was measured according to the manufacturer’s in-
structions using 800 µL of blood for each test (COL-EPI 
and COL-ADP). 
Results are reported as closure times in seconds for 
COL/EPI (increased by aspirin and NSAID) and COL/
ADP cartridges (variably affected by ADP receptor dis-
orders and clopidogrel). The ranges considered normal 
were 85-165 s for the COL/EPI closure time and 71-118 s 
for the COL/ADP(6-9).
STATISTICAL METHODS
Statistical software IBM SPSS Statistics version 21 was 
used in all statistical procedures. Normality of data dis-
tribution was assessed with Kolmogorov-Smirnov test; 
based on these results and total sample size, appropriate 
nonparametric test was used in following analyses. Dif-
ferences between HD and CAPD groups in categorical 
variables were analyzed with χ2-test and differences in 
quantitative variables with Mann-Whitney u test. Spear-
man correlation coefficients were calculated between age, 
duration of treatment, COL/EPI and COL/ADP levels. All 
p values below 0.05 were considered significant. 
RESuLTS
Differences between HP and PD groups in categorical 
patient characteristics are shown in Table 1. There were 
no significant differences in gender, diagnosis, EPO 
(erythropoietin), statin, COL/EPI and COL/ADP groups, 
except for LMWH prevalence in HD group that was sig-
nificantly higher compared to CAPD group (p <0.001).
There were no significant differences in COL/EPI and 
COL/ADP tests (Fig. 1). 
However, more than 50% of HD patients had COL/EPI 
levels higher than 165 s, i.e. delayed closure time.
Differences between HP and PD groups in quantitative 
patient characteristics.
Differences between HD and PD groups in quantitative 
patient characteristics are shown in Table 2. Significant 
differences were noted in age (HD group was signifi-
cantly older; p=0.025) and platelet count (higher levels 
in PD group; p=0.017).
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Table 1








p HD N=32 
CAPD 
N=12 
n % n % 
Gender Male 19 59.4 5 41.7 0.293 Female 13 40.6 7 58.3 
Dg 
Hypertension 9 28.1 3 25.0 
0.796 
Diabetes 6 18.8 1 8.3 
Glom/Pye 5 15.6 4 33.3 
HUS/TTP 2 6.3 1 8.3 
Congenital 5 15.6 1 8.3 
Other 5 15.6 2 16.7 
EPO No 8 25.0 2 16.7 0.557 Yes 24 75.0 10 83.3 
LMWH No 2 6.3 12 100.0 <0.001 Yes 30 93.8 0 0.0 
Statin No 30 93.8 9 75.0 0.081 Yes 2 6.3 3 25.0 
COL/EPI  
<85 s 2 6.3 1 8.3 
0.245 85-165 s 13 40.6 8 66.7 
>165 s 17 53.1 3 25.0 
COL/ADP  
<71s 4 12.5 0 0.0 
0.294 71-118 s 17 53.1 9 75.0 







Differences between HD and PD groups in quantitative patient characteristics (Mann-Whitney U test)
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DISCuSSION
Previous studies confirmed the existence of dysfunction 
of primary hemostasis in patients with ESRD measured 
by PFA-100, a platelet function analyzer, and the ability of 
HD to correct some part of hemostatic disturbances(5,10). 
It was also found that 60% of dialysis patients had 
prolonged in vitro closure time measured by PFA(10). In 
our study, there was no statistical difference in platelet 
function measured by using the platelet function analyzer 
(PFA-100) and expressed as in vitro closure time between 
HD and PD patient groups. However, it is indicative that 
more than 50% of HD patients had COL/EPI test values 
above the upper limit. These findings could be clinically 
correlated with a higher chance for prolonged bleeding 
in HD patients. The number of patients included in the 
study in both groups was relatively small and this could 
be the possible reason for statistically nonsignificant 
difference in platelet function expressed as closure time.
Furthermore, these findings could be correlated to the 
fact that hemodialysis patients received LMWH, which 
was not administered to PD patients. It was already ob-
served in a clinical study that platelet dysfunction exist-
ed in approximately half of the chronic HD patients and 
did not improve after HD, regardless of the anticoagula-
tion regimen used(11). 
In our study, we also found a statistically significantly 
lower level of platelets in HD group compared to PD 
(p=0.017), although platelet counts were within the ref-
erence range in both groups. It is consistent with previ-
ous observations from different clinical studies, which 
showed that in predialysis patients, as well as in HD pa-
tients, platelet count tended to be reduced1 in the range 
of 175.000-180.000/mm3 compared with 250.000/mm3 
in healthy controls. In PD patients, platelet counts have 
been reported to be closer to the normal range(12-14). 
Another study that compared the effects of dialysis with 
four different heparin protocols, using either unfrac-
tionated heparin or LMWH in two different dosages, 
showed that decreases in platelet counts were similar 
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Group n Minimum Maximum 
          Percentile 




HD 32 6.00 126.00 17.25 36.50 65.00
0.094
CAPD 12 4.00 144.00 9.50 16.00 35.75
Age 
HD 32 22.00 88.00 51.00 62.50 75.00
0.025
CAPD 12 24.00 67.00 43.50 51.00 60.50
TT 
HD 31 41.00 94.00 56.00 64.00 71.00
0.432
CAPD 12 42.00 95.00 54.75 68.50 75.75
TV 
HD 31 153.00 191.00 162.00 168.00 175.00
0.989
CAPD 11 153.00 187.00 158.00 168.00 173.00
E 
HD 32 2.72 4.24 3.22 3.54 3.77
0.370
CAPD 12 2.26 5.15 3.40 3.66 3.84
Hgb 
HD 32 76.00 127.00 104.50 111.50 119.00
0.989
CAPD 12 87.00 139.00 97.00 113.50 118.50
Plt 
HD 32 111.00 413.00 149.00 173.00 209.00
0.017
CAPD 12 150.00 302.00 186.75 226.50 265.00
MPV 
HD 32 6.70 12.40 7.90 8.50 9.10
0.926
CAPD 12 6.30 9.70 7.58 8.80 9.25
L 
HD 32 2.70 12.80 5.03 6.05 7.63
0.823
CAPD 12 3.50 12.60 4.63 5.60 7.68
COL/EPI 
(s) 
HD 32 65.00 300.00 119.50 170.50 201.75 0.215
CAPD 12 81.00 300.00 100.00 123.50 175.25
COL/ADP 
(s) 
HD 32 32.00 300.00 81.00 103.00 171.00
0.580




with all anticoagulation regimens used(12,15,16). Besides 
the statistically significantly lower platelet level in HD 
group, patients in this group were also older compared 
to CAPD group.
CONCLuSION
In the present study, we found no statistical difference in 
platelet function measured by the platelet function ana-
lyzer (PFA-100) and expressed as in vitro closure time 
between HD and PD patient groups, but it is indicative 
that more than 50% of HD patients had COL/EPI test 
values above the upper limit, supporting the possibility 
of clinical correlation with a higher chance for increased 
or prolonged bleeding in HD patients. According to the 
results of this study, we can conclude that PD as a meth-
od of renal replacement therapy showed better safety 
profile concerning platelet function, with less reduction 
in platelet count and no need for LMWH. The sensitivity 
of the test and clinical relevance of these findings should 
be further investigated in a larger study with more pa-
tients included.
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Završni stadij kronične bubrežne bolesti obilježen je različitim prokoagulantnim odstupanjima koja dovode 
do razvoja tromboembolijskih komplikacija uz istodobno poremećenu funkciju trombocita s posljedičnim po-
rastom rizika za nastanak krvarenja. Točna etiologija složenih hemostatskih poremećaja u završnom sta-
diju kronične bubrežne bolesti nije u potpunosti razjašnjena. Cilj ovoga istraživanja bio je usporediti učinak 
hemodijalize i peritonejske dijalize na funkciju tromobocita kod bolesnika u završnom stadiju kronične bu-
brežne bolesti primjenom analizatora funkcije trombocita (PFA-100) koji in vitro stimulira proces aktivacije i 
agregacije trombocita. Ispitivanje je provedeno na 2 testa (COL/EPI i COL/ADP) koji mjere vrijeme potrebno 
cirkulirajućoj krvi da okludira membranu obloženu kolagenom i adrenalinom (COL/EPI) odnosno kolagenom 
i ADP-om (COL/ADP). U istraživanje su bili uključeni bolesnici na hemodijalizi (n=32) odnosno peritonejskoj 
dijalizi (n=12). Premda nije zabilježena statistički značajna razlika između testova COL/EPI i COL/ADP, indi-
kativno je da su u više od 50% ispitanika na hemodijalizi vrijednosti testa COL/EPI bile iznad gornje granice 
referentnog intervala. Ovi rezultati mogu se povezati s većom mogućnosti krvarenja u bolesnika na hemodi-
jalizi. Uz to, bolesnici na hemodijalizi bili su značajno stariji te su imali statistički značajno niži broj trombocita 
u odnosu na ispitanike na peritonejskoj dijalizi.
Ključne riječi: funkcija trombocita, završni stadij kronične bubrežne bolesti, hemodijaliza, peritonejska dijaliza
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